National trends in ambulatory oral anticoagulant use

Geoffrey D. Barnes, Eleanor Lucas, George Caleb Alexander, Zachary D. Goldberger

Research output: Contribution to journalArticle

Abstract

Background Four direct oral anticoagulants (DOACs) have been brought to market for the treatment of nonvalvular atrial fibrillation and venous thromboembolism. Many forces, including numerous positive trial results, emerging safety concerns, marketing, and promotion, may shape DOAC adoption by providers. However, relatively little is known regarding their ambulatory utilization compared with warfarin, as well as the degree to which they have decreased under-treatment of atrial fibrillation. Methods We used the IMS Health National Disease and Therapeutic Index, a nationally representative audit of outpatient office visits, to estimate the use of warfarin and DOACs between 2009 and 2014. Results Overall, visits with anticoagulation use increased from 2.05 (95% confidence interval [CI], 1.82-2.27) to 2.83 (95% CI, 2.49-3.17) million (M) quarterly visits (P

Original languageEnglish (US)
Pages (from-to)1300-1305e5
JournalAmerican Journal of Medicine
Volume128
Issue number12
DOIs
StatePublished - Dec 1 2015

Fingerprint

Anticoagulants
Warfarin
Atrial Fibrillation
Confidence Intervals
Office Visits
Venous Thromboembolism
Marketing
Outpatients
Therapeutics
Safety
Health

Keywords

  • Anticoagulants
  • Atrial Fibrillation
  • Venous Thromboembolism
  • Warfarin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

National trends in ambulatory oral anticoagulant use. / Barnes, Geoffrey D.; Lucas, Eleanor; Alexander, George Caleb; Goldberger, Zachary D.

In: American Journal of Medicine, Vol. 128, No. 12, 01.12.2015, p. 1300-1305e5.

Research output: Contribution to journalArticle

Barnes, Geoffrey D. ; Lucas, Eleanor ; Alexander, George Caleb ; Goldberger, Zachary D. / National trends in ambulatory oral anticoagulant use. In: American Journal of Medicine. 2015 ; Vol. 128, No. 12. pp. 1300-1305e5.
@article{94331686d5684292b988d181eabd42bd,
title = "National trends in ambulatory oral anticoagulant use",
abstract = "Background Four direct oral anticoagulants (DOACs) have been brought to market for the treatment of nonvalvular atrial fibrillation and venous thromboembolism. Many forces, including numerous positive trial results, emerging safety concerns, marketing, and promotion, may shape DOAC adoption by providers. However, relatively little is known regarding their ambulatory utilization compared with warfarin, as well as the degree to which they have decreased under-treatment of atrial fibrillation. Methods We used the IMS Health National Disease and Therapeutic Index, a nationally representative audit of outpatient office visits, to estimate the use of warfarin and DOACs between 2009 and 2014. Results Overall, visits with anticoagulation use increased from 2.05 (95{\%} confidence interval [CI], 1.82-2.27) to 2.83 (95{\%} CI, 2.49-3.17) million (M) quarterly visits (P",
keywords = "Anticoagulants, Atrial Fibrillation, Venous Thromboembolism, Warfarin",
author = "Barnes, {Geoffrey D.} and Eleanor Lucas and Alexander, {George Caleb} and Goldberger, {Zachary D.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.amjmed.2015.05.044",
language = "English (US)",
volume = "128",
pages = "1300--1305e5",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - National trends in ambulatory oral anticoagulant use

AU - Barnes, Geoffrey D.

AU - Lucas, Eleanor

AU - Alexander, George Caleb

AU - Goldberger, Zachary D.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background Four direct oral anticoagulants (DOACs) have been brought to market for the treatment of nonvalvular atrial fibrillation and venous thromboembolism. Many forces, including numerous positive trial results, emerging safety concerns, marketing, and promotion, may shape DOAC adoption by providers. However, relatively little is known regarding their ambulatory utilization compared with warfarin, as well as the degree to which they have decreased under-treatment of atrial fibrillation. Methods We used the IMS Health National Disease and Therapeutic Index, a nationally representative audit of outpatient office visits, to estimate the use of warfarin and DOACs between 2009 and 2014. Results Overall, visits with anticoagulation use increased from 2.05 (95% confidence interval [CI], 1.82-2.27) to 2.83 (95% CI, 2.49-3.17) million (M) quarterly visits (P

AB - Background Four direct oral anticoagulants (DOACs) have been brought to market for the treatment of nonvalvular atrial fibrillation and venous thromboembolism. Many forces, including numerous positive trial results, emerging safety concerns, marketing, and promotion, may shape DOAC adoption by providers. However, relatively little is known regarding their ambulatory utilization compared with warfarin, as well as the degree to which they have decreased under-treatment of atrial fibrillation. Methods We used the IMS Health National Disease and Therapeutic Index, a nationally representative audit of outpatient office visits, to estimate the use of warfarin and DOACs between 2009 and 2014. Results Overall, visits with anticoagulation use increased from 2.05 (95% confidence interval [CI], 1.82-2.27) to 2.83 (95% CI, 2.49-3.17) million (M) quarterly visits (P

KW - Anticoagulants

KW - Atrial Fibrillation

KW - Venous Thromboembolism

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=84947865925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947865925&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2015.05.044

DO - 10.1016/j.amjmed.2015.05.044

M3 - Article

C2 - 26144101

AN - SCOPUS:84947865925

VL - 128

SP - 1300-1305e5

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 12

ER -